Lv64
1666 积分 2025-02-28 加入
Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis
7小时前
已关闭
Microstructural and neural impairment of the ocular surface induced by HER2-targeted ADCs: a prospective longitudinal study with ultrastructural insights
2天前
已完结
A multicenter phase II trial of nab‐paclitaxel and capecitabine in HER‐2 negative and triple‐ negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
2天前
已完结
Gastrointestinal inflammation plays a critical role in chemotherapy-induced nausea and vomiting
6天前
已完结
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
6天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
7天前
已完结
Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline
8天前
已完结
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
8天前
已完结
Efficacy of Capecitabine Monotherapy as the First-line Treatment of Metastatic HER2-negative Breast Cancer
21天前
已完结
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
21天前
已完结
皖公网安备34019202002308
